Viking Therapeutics, Inc. (VKTX): R&D Expense
$344.95M
Year ended 2025-12-31
$509.32M
Trailing 12 months to 2026-06-30
+85.3%
3-year compound annual growth
+61.0%
5-year compound annual growth
+47.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $344.95M | +239.4% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $101.64M | +59.3% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $63.81M | +17.6% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $54.23M | +20.6% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $44.98M | +40.9% | 2024-02-07, From 2021-01-01 |
| 2020-12-31 | $31.93M | +35.5% | 2022-02-09, From 2020-01-01 |
| 2019-12-31 | $23.56M | +23.7% | 2021-02-17, From 2019-01-01 |
| 2018-12-31 | $19.04M | +38.6% | 2020-02-26, From 2018-01-01 |
| 2017-12-31 | $13.74M | +52.7% | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | $9.00M | +29.2% | 2018-03-07, From 2016-01-01 |
| 2015-12-31 | $6.97M | -68.7% | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | $22.22M | n/a | 2016-03-08, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $344.95M | +239.4% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare VKTX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗